Immunotherapy add-on ‘fails to improve survival’ in elderly with NSCLC
A real-world study shows adding a checkpoint inhibitor to chemotherapy in older patients doesn’t replicate the benefit seen in trials
The rapid adoption of immunotherapy in first-line treatment of elderly patients with advanced non-small-cell lung cancer (NSCLC) has not improved survival in this cohort, a study suggests.
Noting that guidelines now recommend incorporating the checkpoint inhibitor pembrolizumab into treatment, medical oncologist Dr Kenneth Kehl, of Harvard Medical School in Boston, US, and colleagues, set out to evaluate survival in older patients who didn’t meet original clinical trial criteria.
